Disease burden of cervical cancer and breast cancer in Chinese women in 1990 and 2019

YU Xi-he; ZHANG Jing-ru; JIANG Hai-rui

doi:10.11847/zgggws1136776

Volume 38 Issue 5

May 2022

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of Public Health > 2022 > 38(5): 534-538

YU Xi-he, ZHANG Jing-ru, JIANG Hai-rui, . Disease burden of cervical cancer and breast cancer in Chinese women in 1990 and 2019[J]. Chinese Journal of Public Health, 2022, 38(5): 534-538. doi: 10.11847/zgggws1136776

Citation:

YU Xi-he, ZHANG Jing-ru, JIANG Hai-rui, . Disease burden of cervical cancer and breast cancer in Chinese women in 1990 and 2019[J]. Chinese Journal of Public Health, 2022, 38(5): 534-538. doi: 10.11847/zgggws1136776

Citation:

PDF( 515 KB)

Disease burden of cervical cancer and breast cancer in Chinese women in 1990 and 2019

doi: 10.11847/zgggws1136776

School of Public Health, Jilin University, Changchun, Jilin Province 130021, China

Received Date: 2021-09-06
Available Online: 2022-04-29
Publish Date: 2022-05-20

Abstract

Abstract

Objective To analyze levels and changes of morbidity, mortality and disease burden of breast and cervical cancer among Chinese women in 1990 and 2019 and to provide a reference for developing effective strategies on breast and cervical cancer prevention and control and reducing relevant disease burden in the population. Methods The data of 1990 and 2019 on morbidity and mortality of breast and cervical cancer for global and Chinese women were extracted from the dataset of the Global Burden of Diseases (GBD). Disability-adjusted life years (DALY), years of life lost (YLL), and years lived with disability (YLD) were calculated to assess disease burden of breast and cervical cancer among the women. Results In 2019 in China, the number of morbidity and mortality were 368 400 and 93 500 for female breast cancer, with the increases of 354.25% and 125.85% compared to those in 1990; while for cervical cancer, the number of morbidity and mortality were 109 800 and 53 400, with the increases of 169.78% and 102.27%, respectively. The morbidity, mortality, DALY, YLL, YLD and their standardization rates for female breast cancer and cervical cancers increased with age, reaching higher levels after the age of 55 in both 1990 and 2019. The DALY for female breast cancer and cervical cancer were 2 877 200 person-years and 1 622 200 person-years in 2019, with the increases of 102.12% and 89.64% compared to those in 1990. Conclusion The disease burden of breast and cervical cancer among women in China increased significantly in 2019, suggesting that the prevention and control of the cancer should be further strengthened.
- breast cancer,
- cervical cancer,
- disability-adjusted life years,
- disease burden

FullText(HTML)

References(25)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2018, 68(6): 394 – 424. doi: 10.3322/caac.21492
[2]	Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941 – 1953. doi: 10.1002/ijc.31937
[3]	Abbas KM, Van Zandvoort K, Brisson M, et al. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study[J]. Lancet Global Health, 2020, 8(4): e536 – e544. doi: 10.1016/S2214-109X(20)30022-X
[4]	陈万青, 李贺, 孙可欣, 等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5 – 13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002
[5]	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990 – 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1204 – 1222. doi: 10.1016/S0140-6736(20)30925-9
[6]	Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990 – 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145 – 1158. doi: 10.1016/S0140-6736(19)30427-1
[7]	Vos T, Flaxman AD, Naghavi M, et l. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 – 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2163a – 2196. doi: 10.1016/S0140-6736(12)61729-2
[8]	GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990 – 2013: quantifying the epidemiological transition[J]. Lancet, 2015, 386(10009): 2145 – 2191. doi: 10.1016/S0140-6736(15)61340-X
[9]	李贺, 郑荣寿, 张思维, 等. 2014年中国女性乳腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2018, 40(3): 166 – 171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002
[10]	李道娟, 师金, 靳晶, 等. 宫颈癌的流行病学趋势[J]. 中华肿瘤杂志, 2021, 43(9): 912 – 916. doi: 10.3760/cma.j.cn112152-20190904-00573
[11]	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990 – 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223 – 1249. doi: 10.1016/S0140-6736(20)30752-2
[12]	Sharma R. Examination of incidence, mortality and disability - adjusted life years and risk factors of breast cancer in 49 Asian countries, 1990 – 2019: estimates from Global Burden of Disease Study 2019[J]. Jpn J Clin Oncol, 2021, 51(5): 826 – 835. doi: 10.1093/jjco/hyab004
[13]	Qiu HB, Cao SM, Xu RH. Cancer incidence, mortality, and burden in China: a time - trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10): 1037 – 1048. doi: 10.1002/cac2.12197
[14]	Ji P, Gong Y, Jin ML, et al. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017[J]. Front Oncol, 2020, 10: 650. doi: 10.3389/fonc.2020.00650
[15]	宇传华, 白建军. 社会人口指数(SDI)的概念及其应用[J]. 公共卫生与预防医学, 2020, 31(1): 5 – 10. doi: 10.3969/j.issn.1006-2483.2020.01.002
[16]	陈正超, 张启军, 王秋艳, 等. 吉林育龄妇女乳腺癌、宫颈癌筛查覆盖水平及影响因素分析[J]. 中国公共卫生, 2017, 33(8): 1170 – 1173. doi: 10.11847/zgggws2017-33-08-03
[17]	王乐, 张玥, 石菊芳, 等. 中国女性乳腺癌疾病负担分析[J]. 中华流行病学杂志, 2016, 37(7): 970 – 976. doi: 10.3760/cma.j.issn.0254-6450.2016.07.013
[18]	张瑞芳. 空腹血糖升高对女性乳腺癌复发的影响 [D]. 石家庄: 河北医科大学, 2016.
[19]	Li N, Deng YJ, Zhou HL, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017[J]. J Hematol Oncol, 2019, 12(1): 140. doi: 10.1186/s13045-019-0828-0
[20]	曹燕鸣. 宫颈癌患病因素及晚期宫颈癌患者生存质量研究 [D]. 长沙: 中南大学, 2013.
[21]	Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444 – 457. doi: 10.1158/1055-9965.EPI-16-0858
[22]	刘威, 王黎君, 齐金蕾, 等. 1990 — 2017年中国女性乳腺癌疾病负担分析[J]. 中华流行病学杂志, 2021, 42(7): 1225 – 1230. doi: 10.3760/cma.j.cn112338-20200908-01139
[23]	程婷婷, 安家祯, 吕美玲, 等. 中国西北地区年轻女性乳腺癌临床病理特征及其分子分型[J]. 临床医学研究与实践, 2021, 6(13): 25 – 28.
[24]	孙晓东, 刘敏, 鲍慧, 等. 不同年龄段宫颈癌患者的病理特点及预后分析[J]. 现代肿瘤医学, 2018, 26(11): 1766 – 1769. doi: 10.3969/j.issn.1672-4992.2018.11.029
[25]	侯宜坦, 江冬冬, 刘晓君, 等. 武汉市社区老年人慢性病共病现状及相关因素分析[J]. 中国公共卫生, 2020, 36(11): 1604 – 1607. doi: 10.11847/zgggws1122572